Study on HBV-related acute-on-chronic liver failure risk factors and novel predictive survival model.
10.3760/cma.j.cn501113-20211110-00543
- Author:
Yu Hui TANG
1
;
Xiao Xiao ZHANG
1
;
Si Yu ZHANG
1
;
Lu Yao CUI
1
;
Yi Qi WANG
1
;
Ning Ning XUE
1
;
Lu LI
1
;
Dan Dan ZHAO
1
;
Yue Min NAN
1
Author Information
1. Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.
- Publication Type:Journal Article
- Keywords:
Acute-on-chronic liver failure;
Hepatitis B virus;
Prognosis;
Risk factors
- MeSH:
Humans;
Hepatitis B virus;
Hepatic Encephalopathy/complications*;
Acute-On-Chronic Liver Failure/diagnosis*;
End Stage Liver Disease/complications*;
Severity of Illness Index;
Risk Factors;
ROC Curve;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Hepatology
2023;31(1):84-89
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To identify the predisposing factors, clinical characteristics, and risk factors of disease progression to establish a novel predictive survival model and evaluate its application value for hepatitis B virus-related acute-on-chronic liver failure. Methods: 153 cases of HBV-ACLF were selected according to the guidelines for the diagnosis and treatment of liver failure (2018 edition) of the Chinese Medical Association Hepatology Branch. Predisposing factors, the basic liver disease stage, therapeutic drugs, clinical characteristics, and factors affecting survival status were analyzed. Cox proportional hazards regression analysis was used to screen prognostic factors and establish a novel predictive survival model. The receiver operating characteristic curve (ROC) was used to evaluate predictive value with the Model for End-Stage Liver Disease (MELD) and the Chronic Liver Failure Consortium Acute-on-Chronic Liver Failure score (CLIF-C ACLF). Results: 80.39% (123/153) based on hepatitis B cirrhosis had developed ACLF. HBV-ACLF's main inducing factors were the discontinuation of nucleos(t)ide analogues (NAs) and the application of hepatotoxic drugs, including Chinese patent medicine/Chinese herbal medicine, non-steroidal anti-inflammatory drugs, anti-tuberculosis drugs, central nervous system drugs, anti-tumor drugs, etc. 34.64% of cases had an unknown inducement. The most common clinical symptoms at onset were progressive jaundice, poor appetite, and fatigue. The short-term mortality rate was significantly higher in patients complicated with hepatic encephalopathy, upper gastrointestinal hemorrhage, hepatorenal syndrome, and infection (P < 0.05). Lactate dehydrogenase, albumin, the international normalized ratio, the neutrophil-to-lymphocyte ratio, hepatic encephalopathy, and upper gastrointestinal bleeding were the independent predictors for the survival status of patients. The LAINeu model was established. The area under the curve for evaluating the survival of HBV-ACLF was 0.886, which was significantly higher than the MELD and CLIF-C ACLF scores (P < 0.05), and the prognosis was worse when the LAINeu score ≥ -3.75. Conclusion: Discontinuation of NAs and the application of hepatotoxic drugs are common predisposing factors for HBV-ACLF. Hepatic decompensation-related complications and infection accelerate the disease's progression. The LAINeu model can predict patient survival conditions more accurately.
